Gyre Therapeutics, Inc. (GYRE) Earnings History
Net Loss22 years of earnings data (2004–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Gyre Therapeutics, Inc. (GYRE) Earnings Overview
As of October 22, 2026, Gyre Therapeutics, Inc. (GYRE) reported trailing twelve-month net income of -$17M, reflecting -55.0% year-over-year growth. The company earned $-0.17 per diluted share over the past four quarters, with a net profit margin of 4.3%.
Looking at the long-term picture, GYRE's historical earnings data spans multiple years. The company achieved its highest annual net income of $12M in fiscal 2024.
Gyre Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including HALO ($414M net income, 22.7% margin), ARDX (-$56M net income, -15.1% margin), PRAX (-$339M net income), GYRE has room to improve margins relative to the peer group. Compare GYRE vs HALO →
GYRE Earnings vs Peers
Earnings metrics vs comparable public companies
GYRE Historical Earnings Data (2004–2025)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5M | -58.4% | $11M | $0.02 | 4.3% | 9.9% |
| 2024 | $12M | +113.0% | $16M | $0.05 | 11.4% | 15.3% |
| 2023 | -$93M | -4137.1% | -$67M | $-1.41 | -81.9% | -59.3% |
| 2022 | $2M | +102.6% | $9M | $0.03 | 2.3% | 9.0% |
| 2021 | -$88M | -58.3% | -$84M | $-2.87 | -1198.3% | -1141.0% |
| 2020 | -$56M | -0.7% | -$57M | $-2.93 | -265.1% | -273.9% |
| 2019 | -$55M | -83.6% | -$57M | $-4.41 | - | - |
| 2018 | -$30M | -39.4% | -$34M | $-2.68 | -500916.7% | -563700.0% |
| 2017 | -$22M | -27.2% | -$22M | $-6.30 | -2118.0% | -2143.6% |
| 2016 | -$17M | -14.8% | -$20M | $-21.76 | -4246.9% | -5117.3% |
| 2015 | -$15M | +54.7% | -$14M | $-49.99 | -843.5% | -788.7% |
| 2014 | -$33M | +30.2% | -$30M | $-101.40 | -11862.9% | -10805.1% |
| 2013 | -$47M | -567.4% | -$47M | $-145.78 | -1287.0% | -1301.1% |
| 2012 | -$7M | +18.0% | -$8M | $-21.95 | -12.1% | -14.1% |
| 2011 | -$9M | -178.3% | -$10M | $-28.31 | -8.7% | -10.0% |
| 2010 | $11M | +127.7% | $13M | $37.80 | 12.7% | 15.3% |
| 2009 | -$39M | -53.6% | -$40M | $-161.39 | -157.2% | -160.9% |
| 2008 | -$26M | +8.6% | -$28M | $-109.24 | -127.8% | -140.1% |
| 2007 | -$28M | -1439.0% | -$32M | $-149.47 | -242.5% | -274.5% |
| 2006 | $2M | +107.2% | $-403,692 | $-9.45 | 7.6% | -1.5% |
| 2005 | -$29M | -20.7% | -$30M | $-11619.85 | -2457.1% | -2537.5% |
| 2004 | -$24M | - | -$24M | $-11511.93 | -642.7% | -652.5% |
Download Data
Export GYRE earnings history in CSV or JSON format
Free sign-in required to download data
GYRE Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
22+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
GYRE — Frequently Asked Questions
Quick answers to the most common questions about buying GYRE stock.
What is GYRE earnings per share (EPS)?
GYRE trailing twelve-month (TTM) diluted EPS is $-0.17, reflecting -55.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2004 to 2025 is available in the table on this page.
What is Gyre Therapeutics, Inc.'s net income?
Gyre Therapeutics, Inc. (GYRE) trailing twelve-month net income is $-17M as of 2025. Earnings declined -55.0% year-over-year. Gyre Therapeutics, Inc. has been profitable for 2 consecutive years.
Is GYRE profitable?
GYRE is not currently profitable on a TTM basis, reporting a net loss of $-17M. Net margin is +4.3%. Investors should monitor for a return to profitability.
What is GYRE's earnings growth rate?
GYRE compound annual EPS growth rates (CAGR): 1-Year: -55.0%, 3-Year: -9.1%, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2004 to 2025.
What are GYRE's profit margins?
Gyre Therapeutics, Inc. net profit margin is +4.3%, operating margin is +9.9%, and gross margin is +95.4%. Below-average margins reflect competitive or cost pressures. Return on Equity is +4.2%.
Is GYRE growing earnings?
GYRE earnings are declining — EPS fell -55.0% year-over-year. TTM net income dropped to $-17M. This contrasts with the 5-year CAGR of N/A.
What was GYRE's best earnings year?
Gyre Therapeutics, Inc.'s highest annual net income on record is $12M, achieved in fiscal year 2024. Earnings history on this page spans 2004 to 2025 and includes all annual and quarterly figures.
What were GYRE's earnings last quarter?
GYRE's most recent reported quarter was Q2 2026. Net income was $-11M with diluted EPS of $-0.12. For a full breakdown of all quarters, see the quarterly earnings table on this page.